Moreover, survivin is overexpressed in melanoma, as well as in most cancer entities of epithelial and hematopoietic origin, and its overexpression is associated with disease progression and poor prognosis in the respective patients [8–10], which makes survivin an excellent candidate for therapeutic vaccinations against cancer [11, 12]. This evidence concerns the gene BIRC5 and melanoma.